stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

OmniAb, Inc.

United States · NASDAQ: OABI · Market cap: · P/E: · P/S:

OmniAb licenses antibody discovery technology to drug developers, helping them find and engineer antibody-based medicines.

OmniAb is a drug discovery tools company. It does not develop or sell its own medicines. Instead, it sells access to a set of specially engineered mice and a software platform that pharmaceutical companies, biotech firms, and academic labs use to discover antibodies — the Y-shaped proteins the immune system uses to recognize and neutralize threats, and which form the backbone of many modern medicines.

OmniAb, Inc. (OABI) License and milestone revenue from antibody discovery platforms: line art illustration of a stylized antibody molecule with Y-shaped arms beside a small transgenic mouse icon and a lab instrument
Antibody discovery licensing
OmniAb earns most of its money licensing its antibody discovery technology to drugmakers.

The core of the business is a barn of genetically modified mice. OmniAb's mice have been engineered so their immune systems produce human antibody genes rather than mouse ones. A drug developer immunizes these mice with a target, and the mice generate fully human antibodies against it. That saves the developer the slow, expensive work of "humanizing" mouse antibodies later. Alongside the mice, OmniAb offers its OmniTaur platform for making antibodies with unusually long, simple binding loops — useful for hard-to-hit targets — and OmniDeep, a software suite that helps partners analyze and engineer the antibodies they find. The company also provides access to its proprietary antibody libraries and screening tools. Customers pay OmniAb in a few ways. There are upfront license fees for access to the technology, annual research payments while a program is active, milestone payments when a drug hits development or approval goals, and royalties if a medicine made with OmniAb technology reaches the market. That royalty stream is the long-term prize: a small cut of sales on drugs the company never had to fund or develop itself. The bet is that a broad portfolio of partnered programs eventually yields a handful of approved medicines, and the royalties compound from there.


The business model is capital-light and high-margin, but it depends entirely on someone else's success. OmniAb earns nothing until partners advance programs, and drug development is slow and failure-prone, so revenue can be lumpy and milestone payments unpredictable. The company has invested heavily in its technology platforms and built out its patent estate, and it has assembled a large roster of industry partners over the years. For investors, the appeal is optionality: a portfolio of shots on goal across many partners, where the company collects a toll on the few that work. The risk is that the toll road stays quiet for a long time.

Saved answer · last researched 16 Nov 2026